ACRX
Acelrx Pharmaceuticals Inc
Acelrx Pharmaceuticals Inc
$ACRX Reports Q1 2023 Financial Results, Divests DSUVIA®, Submits Request for Emergency Use Authorization for Niyad to FDA.
Specialty pharmaceutical company AcelRx reported Q1 2023 financial results with a cash balance of $13.4 million. The company divested DSUVIA® to Alora Pharmaceuticals and submitted an Emergency Use Authorization request for Niyad to the FDA, a lyophilized formulation of Nafamostat. AcelRx plans to initiate a single clinical study for Niyad in H2 of 2023. CEO Vince Angotti mentioned embarking on a new chapter with these updates. AcelRx's conference call for investors is scheduled for May 10, 2023. The company's financial statements must be reviewed in context with the SEC report.
4mo ago
$ACRX